Successfully raised $18.5 million through an underwritten offering of common stock.
Net loss widened to $8.9 million from $7.5 million year-over-year.
Operating expenses increased by $1.35 million due to higher R&D and G&A costs.
New 100% pharmaceutical tariffs pose a significant risk to supply chain and costs.
The Q1 2026 filing reveals a company at a critical crossroads, balancing a strengthened short-term balance sheet against chronic operational losses. While the $18.5 million offering provides a necessary lifeline, the widening net loss and increasing R&D spend highlight the inherent volatility of late-stage biotech development. The company's ability to survive depends entirely on the clinical success of Olvi-Vec and its ability to secure further funding without excessive dilution. Investors must weigh the promising interim clinical data and the strategic manufacturing expansion against the risks of partner-dependency and a precarious cash runway. The synthesis of this filing suggests that while the immediate bankruptcy risk has been mitigated, the long-term viability of Genelux remains tied to binary clinical outcomes and the evolving geopolitical landscape regarding pharmaceutical trade and tariffs.